Prognostic Factors in Squamous Cell Carcinoma of the Vulva: a Retrospective Multicenter Study

The study aim to determine the clinicopathological factors for disease-free survival (DFS) and overall survival (OS) in women with vulvarcancer and to analyze the the possible effect of metformin on survival of the patients.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:The study aim to determine the clinicopathological factors for disease-free survival (DFS) and overall survival (OS) in women with vulvarcancer and to analyze the the possible effect of metformin on survival of the patients.

📊

Key Findings & Data:From 2011 to 2017, medical records of 142patients who underwent primary radical surgery for VC at 6 referral centers in Turkey were collected, retrospectively.

💡

Conclusion & Impact:There was no statistically difference inDFS and OS for patients who had used metformin.

🔬Design:Research Article

📍Scope:2011 Verileri

⚙️Variables:Domain Parameters

Abstract

The study aim to determine the clinicopathological factors for disease-free survival (DFS) and overall survival (OS) in women with vulvarcancer and to analyze the the possible effect of metformin on survival of the patients. From 2011 to 2017, medical records of 142patients who underwent primary radical surgery for VC at 6 referral centers in Turkey were collected, retrospectively. The median ageof the cohort was 67.0 years. 124 patients underwent radical surgery and inguinofemoral lymphadenectomy. The overall recurrencerate was 33.8% within a median follow-up time of 22 months. Five-year DFS and OS rates were 55.8% and 62.6%, respectively.Multivariate analysis showed surgical margin (HR:6.4, p= 0.017 for DFS; HR:13.6, p=0.009 for OS) and lymph node metastasis (HR:4.1, p= 0.014 for DFS; HR: 6.3, p= 0.020 for OS) were the independent prognostic factors. There was no statistically difference inDFS and OS for patients who had used metformin.

Özet

Bu çalışma vulva kanserinde klinikopatolojik faktörlerin ve metforminin hastalıksız sağkalım (DFS) ve genel sağkalım (OS) üzerine etkilerini olan ortaya koymayı amaçlamaktadır. Çalışmada ülkemizde 2011-2017 yılları arasında, 6 referans merkezde vulva kanseri nedeniyle primer radikal cerrahi uygulanan 142 hastanın tıbbi kayıtları retrospektif olarak incelendi. Median yaşı 67.0 olan hastalardan 124’üne radikal cerrahi ve inguinofemoral lenfadenektomi yapıldı. 22 aylık median takip süresince rekürrens oranı %33.8 olarak saptandı. Beş yıllık DFS ve OS oranları sırasıyla % 55.8 ve % 62.6 olarak gösterildi. Çok değişkenli analizlerde cerrahi sınır (HR: 6.4, p= 0.017; DFS için; HR: 13.6, p= 0.009 OS için) ve lenf nodu metastazı (HR: 4.1, p= 0.014 için DFS; HR: 6.3, p = 0.020 OS için) bağımsız prognostik faktörler olarak saptandı. Vulva kanserinde metformin kullanımın DFS ve OS’a istatistiksel olarak etkisi olmadığı görüldü.

🔖

Cite This Article

GÖKÇÜ, M., MEYDANLI, M., AYHAN, A., TOPUZ, S., YÜKSEL, İ. T., ÜLKER, V., SANCI, M., KURU, O., ÇAKIR, İ., AKGÖR, U., TOSUN, Ö., YILDIZ, F., SAKINCI, M., SALMAN, M. C., ÖZGÜL, N., YÜCE, K. (2022). Prognostic Factors in Squamous Cell Carcinoma of the Vulva: a Retrospective Multicenter Study. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 30 - Sayı: 1, 54–62. https://ajindex.com/articles/644744

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (15)

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007
Woelber L, Mahner S, Voelker K, et al: Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res 29: 545-552, 2009
Iacoponi S, Zapardiel I, Diestro MD, et al. Prognostic factors associated with local recurrence in squamous cell carcinoma of the vulva. J Gynecol Oncol 24: 242-248, 2013
Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 13: 522-527, 2003
Bogani G, Cromi A, Serati M, et al. Predictors and patterns of local, regional, and distant failure in squamous cell carcinoma of the vulva. Am J Clin Oncol 40: 235-240, 2017
Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 26: 884-889, 2008
Aragona AM, Cuneo NA, Soderini AH, et al. An analysis of reported independent prognostic factors for survival in squamous cell carcinoma of the vulva: is tumor size significance being underrated? Gynecol Oncol 132: 643-648, 2014
Cheng X, Zang R, Wu X, et al: Recurrence patterns and prognostic factors in Chinese patients with squamous cell carcinoma of the vulva treated with primary surgery. Int J Gynecol Cancer 19: 158-162, 2009
Nicoletto MO, Parenti A, Del Bianco P, et al. Vulvar cancer: prognostic factors. Anticancer Res 30: 2311-2317, 2010
Arvas M, Kahramanoglu I, Bese T, et al. The role of pathological margin distance and prognostic factors after primary surgery in squamous cell carcinoma of the vulva. Int J Gynecol Cancer 28: 623-631, 2018
Chan JK, Sugiyama V, Pham H, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol 104: 636-641, 2007
Ayhan A, Velipasaoglu M, Salman MC, et al. Prognostic factors for recurrence and survival in primary vulvar squamous cell cancer. Acta Obstet Gynecol Scand 87: 1143-1149, 2008
Agha RA, Borrelli MR, Vella-Baldacchino M, et al. The STROCSS statement: Strengthening the reporting of cohort studies in surgery. Int J Surg 46: 198-202, 2017
Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105: 103- 104, 2009
Koh WJ, Greer BE, Abu-Rustum NR, et al. Vulvar Cancer, Version 1.2017, NCCN Clinical Pra